Likewise, literature evidence shows similar findings in colorectal cancer and ER-positive breast cancer, further establishing SLC6A14 as a tumor promoter and a potential drug target for cancer therapy [10,11]. This evidence concerns the gene SLC6A14 and colorectal cancer.